Connect. Collaborate.
Catalyze. Join our team
at DCAT 2024
March 18th - 21st -2024
The Benjamin Royal Sonesta Hotel 125 E 50th St, New York, NY 10022Our Team at DCAT 2024
-
Deepak Sapra
CEO, Pharmaceutical Services and Active Ingredients
-
Gunjan Singh
Vice President and Head of Mature Markets – North America & Europe
-
R Lalitha Kumari
Global Head of Product Management & Head of Sales - US & Canada
-
Kalpesh Kumar Modi
Vice President and Region Head – Europe
-
Juli Asmonga
Associate Vice President – US
-
B Vivek
Executive VP and Global Head – Supply, Demand Planning and Delivery
-
Dr. Rajeev Rehani Budhdev
Executive Vice President – API R&D
-
E Sreedhar
Executive Vice President – API Regulatory Affairs
About DCAT 2024
Scheduled from March 18-21 in New York City, DCAT Week 2024 is positioned as the premier event for the Global Bio/Pharmaceutical Manufacturing Value Chain. Hosted by the not-for-profit Drug, Chemical & Associated Technologies Association (DCAT), the conference brings together a diverse range of industry participants, including innovator and generic drug manufacturers, suppliers, and technology providers.
Host: Drug, Chemical & Associated Technologies Association (DCAT)
DCAT, a not-for-profit organization with a membership model that integrates various industry stakeholders, plays the role of a facilitator in the pharmaceutical and chemical sectors. Its global perspective and member-supported structure position it as a neutral platform for collaboration and knowledge exchange.
Event Objectives
The primary objective of DCAT Week is to serve as a forum for professionals within the Bio/Pharmaceutical Manufacturing Value Chain. Attendees can expect a focus on knowledge dissemination, networking opportunities, and discussions around industry trends and challenges
Inclusive Participation
The event is open to a wide spectrum of participants, encouraging inclusivity among innovators, generic drug manufacturers, suppliers of ingredients, development and manufacturing services, as well as technology providers. This diversity in participation fosters an environment where different perspectives and expertise can be shared for the collective benefit of the industry
Knowledge Exchange
DCAT Week aims to provide a platform for the exchange of knowledge and best practices. Participants can anticipate discussions on the latest innovations and technologies shaping the bio/pharmaceutical sector. The event aims to facilitate a neutral space for industry professionals to learn from one another and stay informed about advancements in drug development and manufacturing.
Member Involvement
DCAT Week relies on the active engagement of its members to contribute to the event's success. The association's member-supported model ensures that the event remains a reflection of the industry's collective intelligence. Member involvement extends beyond the event dates, contributing to a dynamic and ongoing platform for collaborative endeavors.
About Dr.Reddy's API Business
We specialise in manufacturing and supplying a wide range of APIs for generic formulation manufacturers in India and overseas. The company has a diversified portfolio of 180+ active pharmaceutical ingredients, which are used in major therapeutic areas such as gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology. Our API manufacturing facilities adhere to cGMP (ICH Q7) and are inspected on a regular basis by international regulatory bodies. We have eight commercially inspected USFDA production plants, six in India and one each in Mexico and the United Kingdom
Dr. Reddy's API business operates in a number of global markets, including the United States of America, Latin America, Europe, India, Russia, and other CIS nations.
ENQUIRE NOWSustainability
Dr. Reddy's is among the top sustainable pharmaceutical companies globally. We are listed in the sustainability yearbook of S&P 2022 for the second year in a row and the Bloomberg Gender-Equality Index (GEI) for the fifth consecutive year. In addition, we were ranked ninth in the Dow Jones Sustainability Index (DJSI) 2021 among the most sustainable pharmaceutical companies in the world. In our sustainability journey, these accolades are humbling and demonstrate that we're on the right track. These awards recognize our consistent performance in the environment, social, and governance (ESG) framework. Sustainability and ESG are becoming increasingly important topics for all stakeholders, so we will strive to maintain visibility in these areas.
Our Achievements
07/10/2021
The winner of the Best Indian Company in the US - Manufacturing Sector for the year 2021
21/01/2021
Best Supply Chain Team of the Year - Pharma- 2021
03/11/2021
Dr. Reddy’s Laboratories wins “API Supplier of the Year” award at the Global Generics & Biosimilars Awards 2021
07/10/2021
The winner of the Best Indian Company in the US - Manufacturing Sector for the year 2021
21/01/2021
Best Supply Chain Team of the Year - Pharma- 2021
03/11/2021
Dr. Reddy’s Laboratories wins “API Supplier of the Year” award at the Global Generics & Biosimilars Awards 2021
Our API Manufacturing Units
免責事項
このウェブサイト上のいかなる情報も、製品またはサービスへの言及を含め、販売の申し出を構成するものではなく、販売の申し出を表すものと解釈されるものでもありません。有効な特許により保護されている製品は、商用目的で提供または提供されるものではありません。ただし、特定のケースでは、Dr. Reddy の独自の裁量により、現地の法的要件に従って、そのような製品の研究用数量が、規制免除が存在する場所に、インド特許法第 107A 条 (Bolar 免除) に基づく規制提出の目的で提供される場合があります。購入者は、それぞれの市場における特許シナリオを含む製品またはサービスについて独自の評価を行う必要があり、すべての特許関連法的責任を負うことになります。Dr. Reddy は、商品性、特定目的への適合性、および非侵害の保証を含むがこれらに限定されない、明示または黙示を問わずすべての保証を否認します。